Health and Fitness Health and Fitness
Thu, July 22, 2010
[ 02:00 PM ] - Market Wire
Genzyme Corporation, Shire plc, Protalix BioTherapeutics, Hospira Worldwide and Apache
[ 01:30 PM ] - Market Wire
Impax Laboratories Receives Final FDA Approval for Generic OPANA® ER Tablets
[ 01:27 PM ] - Market Wire
PerkinElmer to Hold Earnings Call on Thursday, August 5, 2010
[ 01:05 PM ] - Market Wire
Vascular Solutions Announces Record Second Quarte .. sults; Net Revenue Increases 14% to $19.5 Million
[ 01:01 PM ] - Market Wire
Human Genome Sciences Announces Second Quarter 2010 Financial Results and Key Developments
[ 12:23 PM ] - Market Wire
AGA Medical to Host Second Quarter EarningsConference Call on Tuesday, Aug. 3, 2010
[ 11:00 AM ] - Market Wire
Atrium Innovations to Hold 2010 Second Quarter Fi .. esults Conference Call and Webcast on August 13th
[ 09:00 AM ] - Market Wire
Bristol-Myers Squibb National Survey Finds a Disp .. oviders and HIV Positive Patients Perspectives on
[ 08:00 AM ] - Market Wire
LifePoint Hospitals to Broadcast Its Second Quarter 2010 Conference Call Live on the Internet
[ 07:00 AM ] - Market Wire
Orthovita to Present at the Canaccord Genuity 30th Annual Growth Conference
[ 06:25 AM ] - Market Wire
Novelos Therapeutics Announces $1.5 Million Registered Direct Offering
[ 06:00 AM ] - Market Wire
Alliance HealthCare Services Schedules Conference .. t to Review Second Quarter 2010 Financial Results
[ 06:00 AM ] - Market Wire
Ligand to Report Second Quarter Results on August 5th
[ 05:30 AM ] - Market Wire
CytRxa?s Tamibarotene Eradicates Cancer in Advanc .. locytic Leukemia After Failure of Other Therapies
[ 05:30 AM ] - Market Wire
St. Jude Medical Reports Second Quarter 2010 Results
[ 05:00 AM ] - Market Wire
Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA® Patent Litigation
[ 05:00 AM ] - Market Wire
International Stem Cell Plans $10 Million Financing Through European Subsidiary
[ 04:30 AM ] - Market Wire
POZEN To Present at The BMO Capital Markets Focus on Healthcare Conference
[ 04:12 AM ] - Market Wire
Dr. Reddya?s Q1 FY11 Financial Results
[ 04:03 AM ] - Market Wire
Laboratory Corporation of America® Holdings Announces 2010 Second Quarter Results
[ 04:01 AM ] - Market Wire
GenMark Diagnostics Schedules Second Quarter Earn .. gs Release and Conference Call for August 9, 2010
[ 04:00 AM ] - Market Wire
Natus Medical to Hold 2010 Second Quarter Financial Results Conference Call on July 29
[ 04:00 AM ] - Market Wire
Antigenics to Report Second Quarter Financial Results on July 29, 2010; Conference Call to Follow
[ 03:30 AM ] - Market Wire
AVEO Pharmaceuticals, Inc. Announces Timing for S .. 10 Financial Results, Webcast and Conference Call
[ 03:30 AM ] - Market Wire
Inspire Announces Date for Conference Call and We .. to Discuss Second Quarter 2010 Financial Results
Wed, July 21, 2010
[ 11:44 PM ] - Market Wire
Covidien dichiara la distribuzione di un dividendo liquido trimestrale
[ 09:30 PM ] - Market Wire
Covidien Declara Dividendo Trimestral em Dinheiro
[ 06:30 PM ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. ehalf of Shareholders of Cypress Bioscience, Inc.
[ 05:59 PM ] - Market Wire
Covidien gibt Quartalsdividende bekannt
[ 03:19 PM ] - Market Wire
Gilead Sciences anuncia resultados financieros segundo trimestre de 2010

Gilead Sciences anuncia resultados financieros segundo trimestre de 2010


Published on 2010-07-21 15:31:05 - Market Wire
  Print publication without navigation


FOSTER CITY, Calif.--([ BUSINESS WIRE ])--Gilead Sciences, Inc. (Nasdaq:GILD) ha anunciado los resultados de sus operaciones correspondientes al trimestre cerrado el 30 de junio, 2010. Los ingresos brutos totales del segundo trimestre de 2010 han sido de $1.930 millones, un ascenso del 17 por ciento en comparacin con los ingresos brutos totales de $1.650 millones del segundo trimestre de 2009.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources